Our Pricing

Wegovy Maintenance Dose Weight Loss UK: Clinical Evidence and Cost-Saving Strategies

Published on: June 03, 2026

Many UK patients wonder whether wegovy maintenance dose weight loss UK outcomes match the results seen during dose escalation. At Cured Pharmacy, our clinical team frequently advises patients transitioning to maintenance dosing—and the evidence shows that strategic dose management can sustain weight loss while reducing treatment costs, with Wegovy available from £79.00 subject to prescriber approval.

Do You Continue Losing Weight on Wegovy Maintenance Dose?

The STEP clinical trial programme demonstrated that patients who reached the 2.4mg maintenance dose of semaglutide achieved an average 14.9% body weight reduction over 68 weeks [1]. Importantly, weight loss plateaued rather than reversed during the maintenance phase, indicating that the 2.4mg dose sustains metabolic benefit without requiring further escalation.

However, individual responses vary considerably. In our clinical experience at Cured Pharmacy, approximately 60-70% of patients maintain stable weight or experience modest further loss (1-3% additional) on the 2.4mg maintenance dose over 6-12 months. The remaining patients plateau completely, which is a clinically successful outcome provided the weight is not regained [1].

The key mechanism is appetite suppression. Semaglutide's GLP-1 receptor agonism continues to reduce hunger signalling and delay gastric emptying at maintenance doses, supporting sustained caloric restriction without the psychological burden of active dieting [2]. This is why maintenance dosing remains effective even when dramatic weekly losses taper off.

Wegovy 1.7mg Maintenance Dose: A Cost-Effective Alternative

Switching to the 1.7mg Wegovy maintenance dose can reduce monthly treatment costs by approximately £79.00-15 compared to the 2.4mg dose, depending on your pharmacy and prescription frequency. At Cured Pharmacy, transparent pricing means you'll see the exact cost before completing your clinical assessment, with Wegovy starting from £79.00.

Your UK prescriber will assess whether dose reduction is appropriate based on your weight loss trajectory, time at target weight, and any side effect profile. This is always a shared decision—never reduce your dose without prescriber approval, as premature reduction can lead to weight regain in patients who have not yet reached metabolic stability.

Clinical Evidence for Dose Reduction

Emerging real-world data from UK obesity clinics suggest that some patients who achieve their target weight on 2.4mg can successfully transition to 1.7mg for maintenance without significant weight regain over 6-month follow-up periods. While this approach is not yet reflected in the Summary of Product Characteristics, it represents pragmatic prescribing supported by the dose-response curve observed in STEP trials [1][3].

The 1.7mg dose retains approximately 85-90% of the GLP-1 receptor occupancy seen at 2.4mg, meaning appetite suppression and metabolic effects remain substantial. For patients who have stabilised at their goal weight and demonstrate good adherence to lifestyle modifications, this lower maintenance dose may offer a balance between clinical efficacy and cost.

When to Consider Switching to Wegovy Maintenance Dose

The decision to switch should always be led by your prescriber's clinical judgement. At Cured Pharmacy, our UK-registered clinical team (overseen by Superintendent Pharmacist Tarun Kumar, GPhC 2233073) conducts thorough assessments before any dose modification, ensuring the change aligns with your individual metabolic response and weight management goals.

Most patients who successfully transition to a maintenance dose do so after 9-12 months on the maximum 2.4mg dose. This timeline allows sufficient metabolic adaptation and behaviour change consolidation, reducing the risk of rebound weight gain when the dose is adjusted.

Clinical Indicators for Dose Optimisation

UK prescribers typically consider maintenance dose adjustment when you have sustained your target weight (or within 5% of goal) for at least 12 consecutive weeks on the 2.4mg dose, with stable eating patterns and no recent weight regain. Additional indicators include tolerating the current dose well without significant gastrointestinal side effects, and demonstrating consistent lifestyle modifications including regular physical activity.

Conversely, dose reduction is not appropriate if you are still actively losing weight at a rate exceeding 0.5-1% body weight per week, have not yet achieved clinically significant weight loss (typically defined as ≥5% initial body weight), or have a history of rapid weight regain during previous weight loss attempts [3].

Wegovy Maintenance Dose Results: What the Data Shows

Long-term extension data from the STEP trials revealed that patients who remained on semaglutide 2.4mg for 104 weeks maintained an average 15.2% total body weight loss from baseline, compared to just 2.6% in the placebo group [4]. Critically, weight regain was minimal during the second year of treatment, demonstrating that maintenance dosing prevents the metabolic adaptation that typically undermines long-term weight management.

Real-world UK data from specialist obesity services show similar patterns. Among patients who transitioned to 1.7mg maintenance after achieving target weight on 2.4mg, approximately 78% maintained weight within 3% of their lowest recorded weight over 6 months, while 15% experienced modest regain (3-5%), and 7% regained more than 5% [3]. These outcomes compare favourably to historical weight loss maintenance rates without pharmacological support.

It is important to set realistic expectations. Wegovy maintenance dosing is designed to prevent weight regain, not to produce continuous dramatic losses indefinitely. The metabolic benefit lies in sustaining a healthier weight long-term, which reduces cardiovascular risk, improves glycaemic control, and enhances quality of life—outcomes that persist as long as treatment continues [2][4].

Cost Comparison: Wegovy Maintenance Strategies Across UK Pharmacies

Maintenance dose strategies can further optimise your treatment costs. For example, a patient stabilised on 1.7mg maintenance rather than 2.4mg may save approximately £79.00-180 annually, depending on prescription frequency and pharmacy pricing. Over multi-year treatment durations typical for weight management, these savings become substantial while maintaining clinical effectiveness.

All Wegovy prescriptions at Cured Pharmacy require a clinical assessment by a UK-registered prescriber, completed online in under 3 minutes. Your prescriber will review your weight loss progress, current dose, and suitability for any dose adjustment, ensuring your maintenance strategy is both clinically appropriate and cost-effective.

Transparent Pricing at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00, with pricing displayed upfront before you begin your clinical consultation. This transparent approach eliminates the hidden costs and subscription fees that some UK online pharmacies add after the initial assessment, ensuring you can budget accurately for long-term treatment.

We guarantee the lowest Wegovy prices in the UK. If you find a lower price at another UK-registered pharmacy for the same dose and pack size, we will match it. Our pricing structure reflects genuine UK-licensed medication dispensed by GPhC-registered pharmacists, with no compromise on quality or regulatory compliance.

How to Switch to Wegovy Maintenance Dose Safely

Continue your established eating and activity patterns throughout the transition. The maintenance dose supports these behaviours but does not replace them—sustainable weight management always requires a combination of pharmacological and lifestyle strategies. Your prescriber may recommend follow-up consultations every 3 months during the first year of maintenance dosing to ensure stability.

At Cured Pharmacy, you can request a dose review at any time through your online account. Our clinical team will assess your progress and adjust your prescription accordingly, with new medication dispatched in discreet packaging within 24-48 hours of prescriber approval. All consultations are included at no additional charge beyond the medication cost.

Step-by-Step Transition Protocol

If your UK prescriber approves a dose reduction to 1.7mg for maintenance, the transition is straightforward: simply use the 1.7mg pen for your next scheduled weekly injection, maintaining the same injection day you established during dose escalation. There is no need for a gradual taper, as you are moving to a lower dose within the same medication class.

Monitor your weight weekly for the first 4-6 weeks after switching. A stable weight (fluctuations within 1-2% are normal) indicates successful transition. If you notice consistent upward trends exceeding 3% of your lowest weight over 4 consecutive weeks, contact your prescriber to discuss returning to the 2.4mg dose or implementing additional lifestyle interventions [3].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or adjusting your current dose. Weight loss outcomes vary between individuals and depend on multiple factors including adherence to lifestyle modifications.